Compare Nuwellis Inc (NUWE) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Procter & Gamble Co — how do they compare? Nuwellis Inc trades at $0.69 (market cap $2.20M), while Procter & Gamble Co trades at $150.55 (market cap $343.34B). The key difference: Procter & Gamble Co is far larger — about 156063.6× Nuwellis Inc's market cap, and Procter & Gamble Co pays a 2.95% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Procter & Gamble Co for 131 Days on average.
| NUWE | PG | |
|---|---|---|
Market Cap | $2.20M | $343.34B |
Volume | 121,544 | 8,662,344 |
Sector | Health | Consumer Staples |
52-Week High | $146.65 | $167.18 |
52-Week Low | $0.68 | $138.10 |
Typical Hold Time | 26 Days | 131 Days |
Enterprise Value | -$1.52M | $369.18B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Procter & Gamble (PG) trades at $150.59, up 1.47% today, with a bullish technical signal from moving averages and a consensus analyst price target of $160.13. The company reported revenue of $84.28 billion in 2025, with net income of $15.97 billion and strong profitability margins. Recent earnings have consistently beaten expectations, and the stock offers a dividend yield with a history of increases.
PG presents a stable investment with consistent earnings and dividend growth, supported by a robust balance sheet. Risks include premium valuation multiples and modest revenue growth outlook. Analyst sentiment is predominantly positive, with 53% buy ratings, but investors should monitor competitive pressures and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
